Emerging Therapeutic Opportunities in Prostate Cancer



Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space. 

Transcript

I think we’ve got some very interesting things going on within prostate cancer. And I bring that to our attention because here in specialty pharmacy we’ve got a lot of opportunities, right. So with prostate cancer, by the time we get to see these patients many times they’re castration-resistant. We begin to see more therapies that maybe don’t have as much of a CNS side effect. So these patients we often want to make sure they’re not having types of falls or anything like that, so we’ve got some developing going on there. I think, also, opportunities around specialty generics. So we should see abiraterone go generic at some point, maybe in the next few months or year, however we see that come down.  

Related Articles

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Top news of the day from across the health care landscape.
Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$